Anaptysbio is a clinical-stage biotechnology company developing novel immunology therapeutics for autoimmune and inflammatory diseases through its proprietary antibody platform. The company's lead candidates—Rosnilimab, ANB033, and ANB101—target distinct immune pathways to treat conditions across rheumatology, gastroenterology, dermatology, and other therapeutic areas. Anaptysbio generates revenue from milestone payments and royalties on partnered programs including dostarlimab (marketed as Jemperli for endometrial cancer by GSK with tiered royalties of 8–25%) and imsidolimab (licensed to Vanda for generalized pustular psoriasis with 10% net sales royalties), while its wholly-owned candidates progress through clinical trials with the goal of eventual commercialization.